Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.41 |
| ▸ | MERTK | Q12866 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pebezertinib SCHEMBL29537331 | 0.88 | JAK3 (0.49) | KDRDDR2JAK3JAK2JAK1 | |
| SCHEMBL24393252 | 0.87 | JAK3 (0.45) | SYKMERTKJAK3JAK2JAK1 | |
| Pebezertinib SCHEMBL29538098 | 0.87 | JAK3 (0.44) | KDRDDR2MERTKAURKBJAK3 | |
| SCHEMBL29250603 | 0.85 | GSK3B (0.47) | SYKKDRDDR2MERTKAURKB | |
| SCHEMBL29537447 | 0.85 | GSK3B (0.47) | SYKKDRDDR2MERTKAURKB | |
| SCHEMBL24393188 | 0.84 | JAK2 (0.46) | SYKMERTKJAK3JAK2JAK1 | |
| SCHEMBL29537096 | 0.83 | MERTK (0.42) | KDRMERTKAURKBJAK3JAK2 | |
| SCHEMBL24393097 | 0.83 | DDR2 (0.47) | KDRDDR2MERTKAURKBJAK3 | |
| Pebezertinib SCHEMBL24392854 | 0.83 | JAK3 (0.54) | KDRDDR2MERTKAURKBJAK3 | |
| SCHEMBL29537623 | 0.83 | DDR2 (0.47) | KDRDDR2MERTKAURKBJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |